RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:1183

Opsoclonus-myoclonus syndrome

low confidenceDisorder

Also known as: Ataxo-opso-myoclonus syndrome · Dancing eye syndrome · Dancing eye-dancing feet syndrome · Kinsbourne syndrome · OMA syndrome · OMS · Opsoclonus-myoclonus-ataxia syndrome · POMA syndrome · Paraneoplastic opsoclonus-myoclonus · Paraneoplastic opsoclonus-myoclonus-ataxia syndrome

Publications

1,691

Trials

3

Interventional, condition-specific

Researchers

994

Distinct authors in sample

Gene link

—

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

Opsoclonus myoclonus syndrome (OMS) is a rare neuroinflammatory disease of paraneoplastic, parainfectious or origin, characterized by opsoclonus, myoclonus, , and behavioral and sleep disorders.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (8)

Opsoclonus-Myoclonus-Ataxia Syndrome · dancing eye syndrome · dancing eye-dancing feet syndrome · oma syndrome · opsoclonus myoclonus syndrome · opsoclonus-myoclonus-ataxia syndrome · paraneoplastic opsoclonus-myoclonus · paraneoplastic opsoclonus-myoclonus-ataxia syndrome

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    1,691 matched papers (992 in last 10 years) Source

  3. Phenotype characterisedPresent

    22 HPO annotations (e.g. Rigidity; Small cell lung carcinoma; Chronic infection) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPresent

    3 matched on ClinicalTrials.gov

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

22

Associated phenotypes · MONDO:0015247

  • Rigidity
  • Small cell lung carcinoma
  • Chronic infection
  • Neoplasm of the lung
  • Myoclonus

Showing 5 of 22 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

5

Drugs / clinical candidates · MONDO_0015247

CTD chemicals (MyDisease.info)

1 associated chemical · 32 pathways. Therapeutic evidence is listed first when present — not a treatment recommendation.

  • Trazodone · therapeutic

Pathways: Melanogenesis; Adipocytokine signaling pathway; Opioid Signalling; Cytokine Signaling in Immune system; Metabolism; Signal Transduction; Disease; Immune System

MyDisease.info · MONDO:0015247

Literature

Is anyone studying this?

1,691

1,691 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

1,691 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

992 in the last 10 years · low confidence

Phrase hits: 1,691 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

994

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Gorman MP5 papers · 2026

    From the Children's Neurosciences (T.R., M.L.), Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre; Department Women and Children's Health (T.R., M.L.), School of Life Course Sciences (SoLCS), King's College London, UK; Division of Neurology (E.A.Y.), Department of Pediatrics, Neurosciences and Mental Health (RI), The Hospital for Sick Children; Faculty of Medicine (E.A.Y.), The University of Toronto, Ontario, Canada; Department of Pediatrics (Y.K.) and Department of Neurology (Y.K.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics (Y.K.), Weill Medical College of Cornell University, New York; Children and Young People's Unit (Paola Angelini), The Royal Marsden, Downs Road, Sutton, Surrey; UCL Great Ormond Street Institute of Child Health (C.H.), Department of Neurology, Great Ormond Street Hospital for Children, London; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; SiRIC RTOP (G.S.), Translational Research Department, PSL Research University, Institut Curie Research Center; INSERM U830 (G.S.), PSL Research University, Institut Curie Research Center; SIREDO Center: Care (G.S.), Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Department of Child and Adolescent Psychiatry (P.S.), King's College London; Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD) Research Team (P.S.), South London and Maudsley NHS Foundation Trust, London, UK; Baylor College of Medicine (T.L.), Texas Children's Hospital, Houston; Kids Neuroscience Centre (R.C.D.), The Children's Hospital at Westmead, Westmead, NSW, Australia; TY Nelson Department of Neurology and Neurosurgery (R.C.D.), The Children's Hospital at Westmead; The Children's Hospital at Westmead Clinical School (R.C.D.), Faculty of Medicine, University of Sydney, NSW, Australia; Pediatric Neurology Department (K.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Saclay, Bicêtre Hospital; National Referral Center for Rare Inflammatory and Auto-Immune Brain and Spinal Diseases (K.D.); Inserm UMR 1184 (K.D.), Immunology of Viral Infections and Autoimmune Diseases, CEA, IDMIT, Le Kremlin Bicêtre, France; Department of Pediatric Hematology and Oncology (B.H.), University Children's Hospital, Koln; Division of Child Neurology (A.K.), University Children's Hospital Bern Inselspital, University of Bern; Department of Pediatric Neurology (A.K.), University Children's Hospital Basel, Switzerland; Department of Pediatrics (Pedro de Alarcon), University of Illinois College of Medicine at Peoria, Peoria IL; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard Medical School, MA; Division of Neurology (W.G.M.), Department of Pediatrics, Children's Hospital Los Angeles; and Department of Neurology (W.G.M.), Keck School of Medicine at the University of Southern California, Los Angeles.

    Papers in Europe PMC
  2. 02
    Khakoo Y5 papers · 2026

    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.

    Papers in Europe PMC
  3. 03
    Finsterer J4 papers · 2025

    Neurology Neurophysiology Center, Vienna, Austria. Electronic address: fifigs1@yahoo.de.

    Papers in Europe PMC
  4. 04
    Garg RK4 papers · 2026

    Department of Neurology, Era's Lucknow Medical College & Hospital, Era University, Lucknow, India.

    Papers in Europe PMC
  5. 05
    Lim M4 papers · 2026

    From the Children's Neurosciences (T.R., M.L.), Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre; Department Women and Children's Health (T.R., M.L.), School of Life Course Sciences (SoLCS), King's College London, UK; Division of Neurology (E.A.Y.), Department of Pediatrics, Neurosciences and Mental Health (RI), The Hospital for Sick Children; Faculty of Medicine (E.A.Y.), The University of Toronto, Ontario, Canada; Department of Pediatrics (Y.K.) and Department of Neurology (Y.K.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics (Y.K.), Weill Medical College of Cornell University, New York; Children and Young People's Unit (Paola Angelini), The Royal Marsden, Downs Road, Sutton, Surrey; UCL Great Ormond Street Institute of Child Health (C.H.), Department of Neurology, Great Ormond Street Hospital for Children, London; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; SiRIC RTOP (G.S.), Translational Research Department, PSL Research University, Institut Curie Research Center; INSERM U830 (G.S.), PSL Research University, Institut Curie Research Center; SIREDO Center: Care (G.S.), Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Department of Child and Adolescent Psychiatry (P.S.), King's College London; Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD) Research Team (P.S.), South London and Maudsley NHS Foundation Trust, London, UK; Baylor College of Medicine (T.L.), Texas Children's Hospital, Houston; Kids Neuroscience Centre (R.C.D.), The Children's Hospital at Westmead, Westmead, NSW, Australia; TY Nelson Department of Neurology and Neurosurgery (R.C.D.), The Children's Hospital at Westmead; The Children's Hospital at Westmead Clinical School (R.C.D.), Faculty of Medicine, University of Sydney, NSW, Australia; Pediatric Neurology Department (K.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Saclay, Bicêtre Hospital; National Referral Center for Rare Inflammatory and Auto-Immune Brain and Spinal Diseases (K.D.); Inserm UMR 1184 (K.D.), Immunology of Viral Infections and Autoimmune Diseases, CEA, IDMIT, Le Kremlin Bicêtre, France; Department of Pediatric Hematology and Oncology (B.H.), University Children's Hospital, Koln; Division of Child Neurology (A.K.), University Children's Hospital Bern Inselspital, University of Bern; Department of Pediatric Neurology (A.K.), University Children's Hospital Basel, Switzerland; Department of Pediatrics (Pedro de Alarcon), University of Illinois College of Medicine at Peoria, Peoria IL; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard Medical School, MA; Division of Neurology (W.G.M.), Department of Pediatrics, Children's Hospital Los Angeles; and Department of Neurology (W.G.M.), Keck School of Medicine at the University of Southern California, Los Angeles. ming.lim@gstt.nhs.uk.

    Papers in Europe PMC
  6. 06
    Pandey S4 papers · 2026

    Department of Neurology, King George's Medical University, Lucknow, India.

    Papers in Europe PMC
  7. 07
    Singhal S4 papers · 2026

    Department of Pulmonary Medicine, TS Misra Medical College, Lucknow, India.

    Papers in Europe PMC
  8. 08
    Zhang B4 papers · 2026

    Department of Neurology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Biostatistics and Research Design Center, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: bo.zhang@childrens.harvard.edu.

    Papers in Europe PMC
  9. 09
    Aguilera-Albesa S3 papers · 2026

    Unidad de Neuropediatría. Servicio de Pediatría. Complejo Hospitalario de Navarra. Servicio Navarro de Salud, Pamplona, España; Navarrabiomed-Fundación Miguel Servet, Pamplona, España.

    Papers in Europe PMC
  10. 10
    Deiva K3 papers · 2026

    From the Children's Neurosciences (T.R., M.L.), Evelina London Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre; Department Women and Children's Health (T.R., M.L.), School of Life Course Sciences (SoLCS), King's College London, UK; Division of Neurology (E.A.Y.), Department of Pediatrics, Neurosciences and Mental Health (RI), The Hospital for Sick Children; Faculty of Medicine (E.A.Y.), The University of Toronto, Ontario, Canada; Department of Pediatrics (Y.K.) and Department of Neurology (Y.K.), Memorial Sloan Kettering Cancer Center, New York, NY; Department of Pediatrics (Y.K.), Weill Medical College of Cornell University, New York; Children and Young People's Unit (Paola Angelini), The Royal Marsden, Downs Road, Sutton, Surrey; UCL Great Ormond Street Institute of Child Health (C.H.), Department of Neurology, Great Ormond Street Hospital for Children, London; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, University of Oxford; Department of Neurology (S.R.I.), Oxford University Hospitals NHS Foundation Trust, UK; SiRIC RTOP (G.S.), Translational Research Department, PSL Research University, Institut Curie Research Center; INSERM U830 (G.S.), PSL Research University, Institut Curie Research Center; SIREDO Center: Care (G.S.), Innovation and Research for Children, Adolescents and Young Adults with Cancer, Institut Curie, Paris, France; Department of Child and Adolescent Psychiatry (P.S.), King's College London; Centre for Interventional Paediatric Psychopharmacology and Rare Diseases (CIPPRD) Research Team (P.S.), South London and Maudsley NHS Foundation Trust, London, UK; Baylor College of Medicine (T.L.), Texas Children's Hospital, Houston; Kids Neuroscience Centre (R.C.D.), The Children's Hospital at Westmead, Westmead, NSW, Australia; TY Nelson Department of Neurology and Neurosurgery (R.C.D.), The Children's Hospital at Westmead; The Children's Hospital at Westmead Clinical School (R.C.D.), Faculty of Medicine, University of Sydney, NSW, Australia; Pediatric Neurology Department (K.D.), Assistance Publique-Hôpitaux de Paris, Hôpitaux Universitaires Paris Saclay, Bicêtre Hospital; National Referral Center for Rare Inflammatory and Auto-Immune Brain and Spinal Diseases (K.D.); Inserm UMR 1184 (K.D.), Immunology of Viral Infections and Autoimmune Diseases, CEA, IDMIT, Le Kremlin Bicêtre, France; Department of Pediatric Hematology and Oncology (B.H.), University Children's Hospital, Koln; Division of Child Neurology (A.K.), University Children's Hospital Bern Inselspital, University of Bern; Department of Pediatric Neurology (A.K.), University Children's Hospital Basel, Switzerland; Department of Pediatrics (Pedro de Alarcon), University of Illinois College of Medicine at Peoria, Peoria IL; Department of Neurology (M.P.G.), Boston Children's Hospital, Harvard Medical School, MA; Division of Neurology (W.G.M.), Department of Pediatrics, Children's Hospital Los Angeles; and Department of Neurology (W.G.M.), Keck School of Medicine at the University of Southern California, Los Angeles.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

3

interventional trials for this specific condition

3 interventional trials matched this specific condition name; none in our sample are currently recruiting.

Data as of 11 September 2026

3 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 86.7th percentile).

low confidence · 86.7th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

3 interventional trials matched after quoted-phrase search and title/condition post-filter.

No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Opsoclonus-myoclonus syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Opsoclonus-myoclonus syndrome" OR "Ataxo-opso-myoclonus syndrome" OR "Dancing eye syndrome" OR "Dancing eye-dancing feet syndrome" OR "Kinsbourne syndrome" OR "OMA syndrome" OR "Opsoclonus-myoclonus-ataxia syndrome" OR "POMA syndrome" OR "Paraneoplastic opsoclonus-myoclonus" OR "Paraneoplastic opsoclonus-myoclonus-ataxia syndrome" OR "opsoclonus myoclonus syndrome"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Opsoclonus-myoclonus syndrome" OR "Ataxo-opso-myoclonus syndrome" OR "Dancing eye syndrome" OR "Dancing eye-dancing feet syndrome" OR "Kinsbourne syndrome" OR "OMA syndrome" OR "Opsoclonus-myoclonus-ataxia syndrome" OR "POMA syndrome" OR "Paraneoplastic opsoclonus-myoclonus" OR "Paraneoplastic opsoclonus-myoclonus-ataxia syndrome" OR "opsoclonus myoclonus syndrome"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 3 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: OMS

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (1691) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity

Ingested 2026-07-26T16:36:39.677Z